Puma Biotech (PBYI) Misses Q4 EPS by 3c

Puma Biotech (NASDAQ: PBYI) reported Q4 EPS of ($0.80), $0.03 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $71.1 million versus the consensus estimate of $53.65 million.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Goldman Sachs sees bond markets as speed limiter for stocks
• Lululemon (LULU) PT Lowered to $115 at Freedom Broker